U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

This material is intended to notify the press release issued on March 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.

The release as fetched from its publisher. ono-pharma.com ↗